^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CHECKvacc (CF33-hNIS-antiPDL1)

    i
    Other names: CF33-hNIS-antiPDL1, CF33 OV, CF33 Expressing hNIS-Anti-PD-L1 Antibody
    Associations

    News

    Trials
    Company:
    Imugene
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    11ms
    CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=9, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=78 --> 9 | Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Sep 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Oncolytic virus • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    CHECKvacc (CF33-hNIS-antiPDL1)
    1year
    Anti-Tumor Immunogenicity of the Oncolytic Virus CF33-hNIS-antiPDL1 against Ex Vivo Peritoneal Cells from Gastric Cancer Patients. (PubMed, Int J Mol Sci)
    CF33-OVs infect, replicate in, express functional proteins, and kill ex vivo GCPM cells with immune-activating effects. CF33-hNIS-antiPDL1 displays real potential for intraperitoneal GCPM therapy.
    Preclinical • Journal • Oncolytic virus • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL10 (Interleukin 10)
    |
    PD-L1 expression • CD8 expression
    |
    CHECKvacc (CF33-hNIS-antiPDL1)
    over1year
    Induction of an inflammatory tumor microenvironment with oncolytic virus CF33-hNIS-antiPD-L1 intratumoral injection in patients with metastatic triple-negative breast cancer (mTNBC) (ESMO 2023)
    Upregulation of PD-L1 within the TME further suggests immune activation by CHECKvacc. The clinical trial is ongoing to further assess dose escalation, tumor response, and the potential for future combination trials with systemic therapies, such as checkpoint blockade and chemotherapy.
    Clinical • Oncolytic virus • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    CHECKvacc (CF33-hNIS-antiPDL1)
    3years
    CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=78, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Oncolytic virus
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-L1 expression • HER-2 negative • PD-1 expression • CTLA4 expression
    |
    CHECKvacc (CF33-hNIS-antiPDL1)
    3years
    CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=78, Not yet recruiting, City of Hope Medical Center
    Clinical • New P1 trial • Oncolytic virus
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    PD-L1 expression • HER-2 negative • PD-1 expression • CTLA4 expression
    |
    CHECKvacc (CF33-hNIS-antiPDL1)
    over3years
    CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. (PubMed, Cancer Gene Ther)
    Following coculture of activated T cells and BxPC-3 with CF33-hNIS-antiPDL1, the cell surface PD-L1 blockade on BxPC-3 cells by virus-delivered anti-PD-L1 antibody increased granzyme B release and prevented virus-induced decrease of perforin release from activated CD8+ T cells. Our results suggest that CF33-IOVs can prime immune checkpoint inhibition of PDAC and enhance antitumor immune killing.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • GZMB (Granzyme B)
    |
    PD-L1 expression
    |
    CHECKvacc (CF33-hNIS-antiPDL1)